• 
• 

Prof. Alicia Morgans, MD, MPH

Is a Genitourinary Medical Oncologist and the Directorof the Survivorship Program at Dana-Farber Cancer Institute. A clinician and investigator,she has expertise in clinical trials and patient-reported outcomemeasures, as well as incorporating patient preferences and beliefsinto clinical decision making. Her research has investigatedcomplications of systemic therapy for prostate cancer survivors,including the study of skeletal, cardiovascular, diabetic, and cognitivecomplications. Her work has been funded by grants fromthe Prostate Cancer Foundation and the Department of Defense.She is a member of the advanced and localized prostate cancertreatment guidelines committee of the American Urologic Association,and is a member of the cardio-oncology committee of theAmerican Heart Association. Since 2016, she has been Presidentof the Medical Advisory Board for ZERO, a non-profit organizationdedicated to supporting education and research funding for prostatecancer research.

• Prof. Dr. Gunhild von Amsberg , Professor of Uro-Oncology specializing insystemic therapy for prostate cancer,Center for Oncology and Martini Clinic
  
• Prof. Dr. Isabelle Scholl , Deputy Director, Institute and Polyclinic for Medical Psychology